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Activation of skeletal muscle in response to acetylcholine release from the
neuromuscular junction triggered by motor neuron firing forms the basis of all
mammalian locomotion. Intricate feedback and control mechanisms, both from within
the central nervous system and from sensory organs in the periphery, provide essential
inputs that regulate and finetune motor neuron activity. Interestingly, in motor neuron
diseases, such as spinal muscular atrophy (SMA), pathological studies in patients have
identified alterations in multiple parts of the sensory-motor system. This has stimulated
significant research efforts across a range of different animal models of SMA in order to
understand these defects and their contribution to disease pathogenesis. Several recent
studies have demonstrated that defects in sensory components of the sensory-motor
system contribute to dysfunction of motor neurons early in the pathogenic process. In
this review, we provide an overview of these findings, with a specific focus on studies
that have provided mechanistic insights into the molecular processes that underlie
dysfunction of the sensory-motor system in SMA. These findings highlight the role that
cell types other than motor neurons play in SMA pathogenesis, and reinforce the need
for therapeutic interventions that target and rescue the wide array of defects that occur
in SMA.
Keywords: spinal muscular atrophy, SMN, sensory-motor circuit, proprioception, motor neuron,
neurodegenaration
INTRODUCTION
Lower motor neurons, whose cell bodies are resident in the ventral gray horn of spinal cord,
represent the “final common pathway” (Sherrington, 1906) through which neuronal activity has
to pass in order to generate the contraction of skeletal muscle required for movement. Whilst
a large proportion of the synaptic inputs controlling lower motor neuron function arise from
descending pathways, including upper motor neurons, pioneering work begun by Sir John Eccles
and colleagues in the 1950s has revealed the additional influence of synaptic inputs arising from
proprioceptive sensory neurons (including group Ia afferents), whose cell bodies are located in the
dorsal root ganglia (DRG) (Eccles et al., 1957; Brown, 1981; Mears and Frank, 1997). These sensory
inputs have been shown to form monosynaptic connections with lower motor neurons (Figure 1),
whereby they can regulate motor neuron firing patterns as part of the monosynaptic spinal stretch
reflex arc as well as in other locomotor behaviors (Rossignol et al., 2006).
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Recent work has begun to uncover the complex molecular
pathways regulating the formation and maintenance of such
sensory-motor connectivity in the spinal cord, highlighting
key roles for pathways incorporating Sema3e–Plxnd1 signaling
(Pecho-Vrieseling et al., 2009) and the RNaseIII protein Dicer
(Imai et al., 2016). Moreover, several studies have highlighted
how disruption of sensory-motor connectivity can result from
perturbations in genes and proteins underlying a diverse range
of neurodegenerative conditions, including; amyotrophic lateral
sclerosis (ALS) (Jiang et al., 2009), post-polio muscular atrophy
(PPMA) (Soliven and Maselli, 1992), and spinal muscular
atrophy (SMA) (see below). In this review we provide an overview
of the contributions that sensory-motor connectivity defects
make to the pathogenesis of SMA, incorporating new insights
into underlying molecular pathways that suggest the existence of
common mechanisms across diverse neuromuscular conditions.
SENSORY-MOTOR DEFECTS IN SPINAL
MUSCULAR ATROPHY (SMA)
SMA is a hereditary form of motor neuron disease, characterized
by degeneration and death of lower (alpha) motor neurons
in the ventral horn of spinal cord (Lunn and Wang, 2008;
Groen et al., 2018b). This leads to progressive proximal muscle
weakness, atrophy and, in severe cases, paralysis and death.
SMA is caused by homozygous deletion of, or other deleterious
variants in, the SMN1 gene, leading to a significant reduction
in the expression of full-length survival motor neuron protein
(SMN). SMN is a ubiquitously expressed protein that has been
implicated in numerous cellular processes, including snRNP
biogenesis, cytoskeletal dynamics, protein homeostasis, and
mitochondrial function and is required for cellular survival.
A detailed discussion of the cellular roles of SMN can be found in
a number of recent review papers [for example (Hosseinibarkooie
et al., 2017; Singh et al., 2017; Chaytow et al., 2018)].
In line with the ubiquitous expression of SMN, SMA is not
solely a disease of the lower motor neuron. For example, it is now
known that multiple different organ systems and cell types are
affected in SMA (Nash et al., 2016), including defects in the heart,
vasculature and skeletal muscles (Hamilton and Gillingwater,
2013; Shababi et al., 2014). Alongside these systemic pathologies,
defects in sensory neurons have been reported in SMA patients,
including abnormal sensory conduction (Duman et al., 2013;
Yonekawa et al., 2013) or complete absence of sensory nerve
action potentials (Yuan and Jiang, 2015; Reid et al., 2016), along
with axonal degeneration and loss of myelinated fibers within
sensory nerves (Korinthenberg et al., 1997; Omran et al., 1998;
Rudnik-Schoneborn et al., 2003). Depending on the type of SMA,
varying structural abnormalities in muscle spindles have been
described, although some of these findings are contradictory
and would require further investigation (Marshall and Duchen,
1975; Bobele et al., 1996; Kararizou et al., 2006). Several studies
conducted on presumed SMA cases (patients diagnosed with
SMA before genetic testing was available for the disease) also
identified degeneration of sensory nerves, glial bundles within
dorsal roots, ballooned neurons and chromatolysis within the
DRG (Marshall and Duchen, 1975; Carpenter et al., 1978;
Shishikura et al., 1983; Murayama et al., 1991). Importantly,
reduced synaptophysin expression has been observed adjacent to
anterior horn neuron cell bodies in SMA patients, indicating a
reduction in the number of or disconnection of afferent nerve
fibers, including sensory synapses (Ikemoto et al., 1996). Not only
do these studies demonstrate defects within the sensory neurons
themselves but they also demonstrate the possibility of alterations
and lack of connectivity at both extremities of the sensory neuron.
Sensory-Motor Defects in Mouse Models
of SMA
The SMA research field has benefited greatly from the availability
of a number of animal models that mimic key pathological
features of SMA, such as motor neuron death, degeneration
of the neuromuscular junction and organ pathology (Hamilton
and Gillingwater, 2013; Edens et al., 2015). Indeed, model
systems of SMA also recapitulate core defects of the sensory
nervous system seen in SMA patients. For example, sensory
neurons cultured from a severe mouse model of SMA show
defects in neurite outgrowth and growth cone morphology,
along with a reduction of beta-actin protein and mRNA in
growth cones (Jablonka et al., 2006) – a phenotype that is
similar to that observed in SMN deficient motor neurons
(Rossoll et al., 2003). In mouse models of SMA, sensory neurons
are smaller, consistent with an appearance of overall reduced
size of DRGs (Shorrock et al., 2018b). Moreover, the ratio
of different subtypes of sensory neurons in SMA DRG is
altered (see Section “Molecular Mechanisms Associated With
Sensory Neuron Dysfunction in SMA and Related Conditions”)
(Shorrock et al., 2018b). It has also been shown that there
is a reduction in myelinated dorsal root axons in SMA mice
compared to controls (Ling et al., 2010) and a reduction
of sensory fibers passing into the ventral horn in SMA
mice (Mentis et al., 2011).
Importantly, in line with what has been observed in SMA
patients, these structural defects occurring in sensory neurons
have also been associated with defects at the level of synapses
formed by sensory neurons in SMA mice (Fletcher and Mentis,
2016). The total number of synapses onto motor neurons in
the lumbar region of the spinal cord is significantly reduced in
mouse models of SMA (Ling et al., 2010). The largest contribution
to this overall reduction of sensory synapses comes from a
reduction in the number of vGlut1-positive synapses which
primarily originate from proprioceptive neurons. This central
feature of sensory-motor pathology has now been observed
across multiple different SMA mouse models, including the
commonly used Taiwanese and delta7 models, suggesting that
it is a conserved feature of the disease (Ling et al., 2010; Mentis
et al., 2011; Shorrock et al., 2018b). Within the lumbar region of
spinal cord, the reduction in proprioceptive synapses onto motor
neurons is most severe at the level of L1 motor neurons and
medial L5 motor neurons (Mentis et al., 2011). Interestingly, this
reduction is observed presymptomatically, (Mentis et al., 2011;
Fletcher et al., 2017) and is associated with significant functional
deficits (Fletcher et al., 2017). Thus, sensory-motor connectivity
defects reported in SMA mice consistently affect DRGs and
Frontiers in Molecular Neuroscience | www.frontiersin.org 2 March 2019 | Volume 12 | Article 59
fnmol-12-00059 March 1, 2019 Time: 16:4 # 3
Shorrock et al. Mechanisms Underlying Sensory-Motor Pathology in SMA
FIGURE 1 | Overview of the sensory-motor system and pathologies observed in SMA. Schematic (A) and immunohistochemical (B) representation of the
sensory-motor system, focusing on structures, cell types, and subcellular compartments that have been implicated in SMA pathogenesis. In (A), the text in green
indicates the primary pathological changes occurring in specific cell types or in specific subcellular compartments. In (B), immunofluorescence was used to label
parvalbumin-expressing cells and projections (proprioceptive neurons; red), neuronal cell bodies (ChAT for motor neurons, beta-III-tubulin for DRG cell bodies;
green), and nuclei (DAPI; blue). Note that only a subgroup of DRG cell bodies express parvalbumin and that other markers such as NF200+ (mechano- and
proprioceptive) and peripherin+ (nociceptive) can also be used to identify other types of sensory neurons. Scale bars: 100 µm (spinal cord and DRG); 20 µm (motor
neuron). DRG, dorsal root ganglion; ChAT, acetylcholine transferase; DAPI, 4,6-diamidino-2-phenylindole; vGlut1, vesicular glutamate transporter 1; NF200,
neurofilament heavy polypeptide (200 kDa).
motor neurons related to the body regions primarily affected in
SMA patients, suggesting that defects occurring in SMA animal
models are comparable to sensory-motor pathology observed in
patients (Figure 1).
SMN Expression Is Required Throughout
the Sensory-Motor System
Whilst motor neuron death is central to the pathogenesis of
SMA, in mouse models motor neuron death is preceded by
dysfunction of motor neuron and neuromuscular transmission
characterized by hyperexcitability, increased input resistance,
and decreased synaptic efficacy (Ling et al., 2010; Mentis
et al., 2011; Fletcher et al., 2017). These functional defects,
in combination with pathological findings that show sensory
neuron and synapse loss in SMA patients and mouse models,
indicate a complex interplay between the various components
of the sensory-motor system eventually leading to motor neuron
defects and death.
As loss of SMN expression is central to SMA pathogenesis,
recent research has aimed to determine the requirements for
SMN expression in the sensory-motor system. In wild-type
mice, SMN is expressed throughout all components of the
sensory-motor system, including DRGs (Shorrock et al., 2018b),
muscle, brain and spinal cord (Lee et al., 2012; Groen et al.,
2018a), as well as peripheral nerves (Hunter et al., 2016). In
Drosophila models of SMA, pan-neuronal restoration of SMN
rescues locomotion and motor rhythm phenotypes (Imlach et al.,
2012). In mouse models of SMA, pan-neuronal SMN restoration
completely rescues motor neuron numbers and the number of
vGlut1+ synapses onto motor neurons (Lee et al., 2012). To
explore this phenomenon further, several research groups have
investigated the requirements of SMN expression by restoring
SMN in specific cell types of the sensory-motor system, using
a range of genetic tools and animal lines (Gogliotti et al., 2012;
Imlach et al., 2012; Martinez et al., 2012; Hao le et al., 2015; Simon
et al., 2016; Fletcher et al., 2017). However, it remains difficult
to generate a consensus from these studies, meaning that the
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exact cell-type and temporal requirements for SMN expression
in the sensory-motor system remain to be fully determined
(Table 1). Overall, however, these studies indicate that motor
neuron death may be primarily due to cell-autonomous effects
while the underlying cause of motor neuron dysfunction has a
larger contribution from defects in proprioceptive neurons which
provide a substantial non-cell autonomous component of motor
neuron pathology. These findings highlight important issues
when considering temporal and tissue specific requirements of
SMN-targeted therapies for SMA as restoring SMN expression
specifically in proprioceptive and motor neurons at the same time
led to the biggest improvement in SMA-associated pathology
compared to restoring SMN expression in either motor or
proprioceptive neurons alone (Fletcher et al., 2017).
The importance of non-cell autonomous effects on motor
neurons is further illustrated by several studies that have
investigated the effect of defects intrinsic to specific types
of sensory neurons on motor neuron function, in otherwise
healthy animals. For example, blocking neurotransmission
specifically in proprioceptive neurons in wild-type mice can
cause severe motor defects, shortened lifespan and motor
neuron dysfunction (Fletcher et al., 2017). Similarly, inhibiting
cholinergic neuron activity in Drosophila causes reduced
locomotion, increased spontaneous rhythmic motor activity
and increased EPSPs at the neuromuscular junction by
reducing excitatory cholinergic input to motor neurons (Imlach
et al., 2012). Likewise, pharmacological inhibition of excitatory
neurotransmission in an embryonic stem cell model of
TABLE 1 | Overview of studies investigating SMN expression requirements in various components of the sensory-motor system.
Model system Neuron subtype Driver(s) Effect of neuron subtype specific SMN
restoration on sensory-motor phenotypes
Reference
Mouse (severe) Motor neuron Hb9-Cre Full rescue of vGlut1+ puncta per 100 µm
perimeter of motor neuron soma
Gogliotti et al., 2012
Complete rescue of cervical, thoracic and
lumbar medial motor column motor neuron
number
Zebrafish Motor neuron mnx1/hb9 Cre Partial rescue of dorsal root ganglion neuron
number
Hao le et al., 2015
(maternal zygotic smn mutant) Rescue of DRG neuron axon length
Complete rescue of motor axon branches total
length
Mouse (delta 7) Motor neuron Chat-Cre Partial rescue of vGlut1+ synapses per motor
neuron soma (L1)
Martinez et al., 2012
Partial rescue of L1 motor neuron number
Mouse (delta 7) Motor neuron Chat-Cre No rescue of vGlut1+ synapses onto motor
neurons (L2)
Fletcher et al., 2017
No rescue of motor neuron firing frequency
Partial rescue of L2 motor neuron number
Proprioceptive neuron Pv-Cre Rescue of vGlut1+ synapses per motor neuron
soma and dendrites (L2)
Correction of motor neuron firing frequency
No rescue of L2 motor neuron number
Drosophila (smn−/−) Motor neuron OK371-Gal4;
OK6-Gal4
No improvement of defective locomotion
velocity, NMJ ePSPs or motor rhythm
Imlach et al., 2012
Cholinergic neuron (including
proprioceptive neurons)
Cha-Gal4 Complete rescue of defective locomotion
velocity, NMJ ePSPs, and motor rhythm
Embryonic stem cell-derived Motor neuron Smn RNAi Reduced motor neuron survival Simon et al., 2016
motor circuit Smn RNAi∗ No reduction of vGlut2 excitatory synapses
onto motor neurons
No change in motor neuron hyperexcitability
Excitatory interneuron Smn RNAi# Loss of vGlut2 excitatory synapses onto motor
neurons
Induced motor neuron hyperexcitability
ChAT, choline acetyltransferase; Cha, choline acetyltransferase; Pv, Parvalbumin alpha; Hb9/mnx1, Motor neuron and pancreas homeobox protein 1; Smn, survival motor
neuron protein; RNAi, RNA interference; L1/2, lumbar segment 1/2; DRG, dorsal root ganglia; NMJ, neuromuscular junction; ePSPs, excitatory postsynaptic potentials.
∗co-cultured with wild-type excitatory interneurons; #co-cultured with wild-type motor neurons.
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the motor circuit induced motor neuron hyperexcitability
but not motor neuron death (Simon et al., 2016). Finally,
mutations in the mechanosensitive ion channel responsible for
mechanosensation of light touch and proprioception, PIEZO2,
cause a neuromuscular disease characterized by muscle atrophy,
aberrant muscle development and function, mild sensory
involvement, delayed motor milestones, and scoliosis (Chesler
et al., 2016; Delle Vedove et al., 2016). Together these studies
indicate that defects within sensory neurons themselves can lead
to both motor neuron and muscle dysfunction in the absence of
defects intrinsic to motor neurons.
In summary, the above work illustrates that SMA mouse
models reliably reflect pathological changes in the sensory-
motor system of SMA patients. Moreover, it also illustrates
the importance of homeostasis of the sensory-motor system:
correct functioning of each of its parts is required for it to
function correctly as a whole. Mechanistically, these studies
have largely focused on motor neuron pathology and SMN
requirements. Further molecular studies will be required to better
understand the cellular pathways that are involved in regulating
these pathological changes. In the next section of this review,
we will focus on studies that have aimed to address this issue,
also drawing on molecular insights obtained by studying other
diseases of the sensory-motor system.
MOLECULAR MECHANISMS
UNDERLYING SENSORY-MOTOR
CONNECTIVITY DEFECTS IN SMA
The presence of sensory-motor connectivity defects in SMA
(as illustrated by the loss of proprioceptive vGlut1+ synapses),
alterations in sensory neuron development, and the requirement
for SMN expression in different neuronal subpopulations have
all been clearly established (Figure 1). In SMA, SMN depletion is
at the basis of each of these pathological changes. However, the
molecular mechanisms that modulate these changes downstream
of SMN depletion are still unclear. It is by further studying
the changes downstream of SMN depletion that we will be
able to better understand why certain cell types are more
sensitive to SMN depletion than others, why defects in certain
cellular pathways affect certain cell types more than others,
and, ultimately, how SMN depletion leads to SMA, including
disruption of sensory-motor connectivity.
Molecular Mechanisms Linked to Motor
Neuron Death and Pathology in SMA
As illustrated by the cell-type specific SMN requirements
discussed above, pathways leading to motor neuron death appear
to be largely cell autonomous. A better understanding of the
molecular mechanisms associated with motor neuron death was
gained from studies that compared gene expression profiles of
vulnerable and resistant pools of motor neurons. These studies
identified differences in basal bioenergetics profiles between
vulnerable and resistant motor neuron pools (Boyd et al., 2017),
as well as differences in activation of the cell death-regulating
protein p53 and differential regulation of its downstream targets
(Murray et al., 2015; Simon et al., 2017). Mechanistically, it
has been shown that the alternative splicing of Mdm2 and
Mdm4 downstream of and concurrently with disrupted snRNP
biogenesis acts synergistically to induce p53 accumulation in
SMA (Van Alstyne et al., 2018). However, despite rescuing
the reduction of MN numbers seen in SMA mice, neither the
inhibition of p53 signaling nor virus-mediated overexpression of
full-length Mdm2 and Mdm4 is able to rescue vGlut1+-synapse
loss (Simon et al., 2017; Van Alstyne et al., 2018).
Other factors have also been linked to motor circuit function
in SMA, including stasimon (Lotti et al., 2012). Decreasing
stasimon expression in zebrafish phenocopied motor axon
branching defects seen in smn morpholino zebrafish, which in
turn could be rescued by overexpressing stasimon. Similarly, in
a Drosophila model of SMA, expressing stasimon in cholinergic
(proprioceptive) neurons, but not motor neurons, rescued
neurotransmitter release at the NMJ and muscle size defects
(Lotti et al., 2012). All of these studies indicate that, while
motor neuron death itself can be rescued by targeting the
pathways that directly lead to motor neuron death (such as
p53 activation, and Mdm2 and Mdm4 missplicing), this does
not rescue motor neuron dysfunction or other motor neuron-
associated phenotypes in models of SMA (Lotti et al., 2012; Van
Alstyne et al., 2018). Other molecular factors such as agrin and
plastin3 that are linked to and important for NMJ organization
and AMPA receptor functioning have also been implicated in
SMA (Zhang et al., 2013; Hosseinibarkooie et al., 2016; Kim
et al., 2017). These factors could be important for the reduced
synaptic transmission seen in SMA. Moreover, complement C1q,
an important factor in postsynaptic pruning, is upregulated in
SMA motor neurons (Zhang et al., 2013); a event which, along
with an increased association of microglia with SMA motor
neurons (Ling et al., 2010), might contribute to the impaired
sensory-motor connectivity observed in SMA.
In summary, the above studies have provided important
insights into the molecular mechanisms that underlie motor
neuron death in SMA. However, in line with previous
pathological and SMN expression studies (see Section “SMN
Expression Is Required Throughout the Sensory-Motor System”),
these studies also illustrate the importance of non cell-
autonomous processes in sensory-motor dysfunction in SMA.
Molecular Mechanisms Associated With
Sensory Neuron Dysfunction in SMA and
Related Conditions
The number of studies investigating the molecular mechanisms
that underlie sensory neuron dysfunction in SMA is limited.
Therefore, adapting biological findings generated from studies
of other, related neuromuscular diseases that are characterized
by sensory neuron dysfunction has been of benefit to the SMA
research field. For example, Charcot-Marie-Tooth (CMT) disease
is a hereditary motor and sensory neuropathy that, depending on
its genetic cause, has a variable clinical presentation. CMT type
2D, caused by mutations in the tRNA synthetase GARS (glycine
tRNA-ligase or GlyRS), has a predominant motor phenotype,
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although sensory defects are also present (Motley et al., 2010).
In CMT2D, sensory defects have been shown to be linked to
a disruption in sensory neuron fate, downstream of increased
expression of mutant GARS (Sleigh et al., 2017). Specifically,
when determining sensory neuron subtypes in DRGs from two
CMT2D mouse models, fewer large cell body NF200-positive
(neurofilament heavy) cell bodies were present in favor of an
increased number of peripherin-positive, smaller neurons (Sleigh
et al., 2017). Taking this observation into the SMA context
provides a possible explanation for the loss of sensory synapses
onto lower motor neurons that occurs in the SMA spinal cord,
as a shift in sensory neuron cell fate would also lead to changes
at the level of their synaptic contacts. Indeed, when investigating
sensory neuron development in the Taiwanese mouse model of
SMA, it was shown that a similar change in sensory neuron
fate occurs when SMN expression levels are reduced: a decrease
in the number of NF200-positive mechano- and proprioceptive
sensory neurons is accompanied by an increase in the number of
peripherin-positive nociceptive sensory neurons (Shorrock et al.,
2018b). Correspondingly, protein levels of GARS were also found
to be changed in the spinal cord of SMA mice, as well as in DRGs,
in a way that is comparable to changes in GARS observed in
mouse models of CMT2D.
The upregulation of GARS in SMA was shown to be regulated
by the E1 ubiquitin-activating enzyme, UBA1. UBA1 expression
has previously been shown to be significantly decreased in SMA
from very early in the pathogenic process and is therapeutically
targetable (Wishart et al., 2014; Powis et al., 2016). When
investigating protein changes that occur downstream of UBA1,
GARS expression was found to depend on UBA1 expression
(Shorrock et al., 2018b). In line with this, GARS-dependent
pathological features of SMA, including altered sensory neuron
fate and loss of proprioceptive synapses in the spinal cord, were
rescued when UBA1 levels were elevated using a gene therapy
approach (Shorrock et al., 2018b). These findings provide an
interesting pathological link between SMA and CMT2D, but
also indicate possible molecular pathways that may underlie
sensory-motor pathology in SMA and provide starting points for
further research. For example, possible mechanistic links related
to disruption of GARS-mediated pathways have been shown to
involve dysfunctional Nrp1 / VEGF and Trk signaling (He et al.,
2015; Sleigh et al., 2017). Mutant GARS can aberrantly bind these
proteins and this aberrant binding is thought to disrupt their
function. However, to what extent these pathways are relevant for
sensory defects associated with SMA remains to be determined.
In addition to defects in Trk and Nrp1/VEGF signaling,
mutations in GARS are known to lead to increased levels
of alpha-tubulin acetylation (d’Ydewalle et al., 2011). Alpha-
tubulin acetylation depends on HDAC activity (Zhang et al.,
2003), and, interestingly, both a broad spectrum HDAC inhibitor
(trichostatin A) as well as a specific HDAC6 inhibitor (tubastatin
A) reversed increases in alpha-tubulin acetylation in a range of
cellular and animal models of CMT2D (d’Ydewalle et al., 2011;
Benoy et al., 2018; Mo et al., 2018). Intriguingly, the broad
spectrum HDAC inhibitor trichostatin A was previously found
to rescue vGlut1+-synapse loss on spinal motor neurons in the
delta7 model of SMA (Mentis et al., 2011). To what extent this
process is also related to alpha-tubulin acetylation or is due
to other effects of HDAC inhibition in SMA remains to be
determined. However, this provides an intriguing possible link
between HDAC inhibition, GARS function, DRG pathology and
sensory synapse loss.
In summary, these findings illustrate how molecular
pathways that were previously identified in other disorders,
such as CMT2D, can assist discovery of novel mechanisms
and therapeutic targets that underlie sensory-motor
connectivity defects in SMA.
CONCLUDING REMARKS
Motor neurons rely on a range of synaptic inputs, both from
within the central nervous system and from sensory neurons
projecting from the periphery, to regulate and finetune their
activity. In SMA, multiple components of this sensory-motor
system have been shown to be disrupted, contributing to motor
neuron dysfunction and death. Several molecular pathways have
now been identified that regulate sensory neuron dysfunction and
these pathways form interesting novel targets for further study
and potential therapy development.
The SMA research field is currently at a defining moment.
The first disease-modifying therapy for SMA was recently
approved, while other therapies are currently in advanced stages
of clinical development (Shorrock et al., 2018a). However, the
fact that current therapies are targeted to the nervous system
specifically and do not benefit all patients equally, illustrates
that fundamental SMA research is still needed, perhaps more
than ever (Groen et al., 2018b). Furthering our understanding
of the molecular mechanisms that underlie pathological changes
occurring in specific cell types, such as sensory neurons, will
aid the discovery of novel therapeutic strategies. Moreover, this
process may be sped up by scrutinizing the existing knowledge
from other, related disorders, as is illustrated by the recent
identification of shared molecular mechanisms between SMA and
CMT2D. Combining advances in these areas of research will
be necessary to be able to eventually provide therapies that will
benefit and support all SMA patients equally and efficiently.
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